DICE Therapeutics
phase study design and dose rationale test active | DICE Therapeutics
Company
Deck Type
Deck date
March 2023
Slide
26 of 59
Similar slides by DICE Therapeutics
See diffirences between slides (animation)
Results
October 2022
phase study design and dose rationale dice lea ama home | DICE Therapeutics
Related slides by other companies
BenevolentAI
Results
March 2023
ben indicative data from phase caveats phase was not powered to meaningfully assess only patients dosed with active per group maximum duration of dosing days score changes typically measured at days mean change from affected in treated areas day bid | BenevolentAI
Dare Bioscience
Investor Presentation
February 2023
dar working to accelerate innovation in women health upcoming program milestones dare | Dare Bioscience
Erasca
Investor Presentation
November 2023
clinical activity of in melanoma was reproducible across phase and phase studies a | Erasca
MaxCyte
Investor Presentation
January 2024
enabled active clinical trials | MaxCyte
Other recent decks by DICE Therapeutics
See all presentations (4 decks)
Results
March 2023
Investor Presentation
March 2023
Results
October 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io